Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 5-Day aspirin course shield the brain from Post-Coiling strokes?

NCT ID NCT04192955

Prevention Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether taking aspirin for five days around the time of brain aneurysm coiling can prevent strokes. About 440 adults with an unruptured brain aneurysm scheduled for coiling-only treatment will receive either aspirin or a placebo. Researchers will check for strokes, both silent and symptomatic, using brain scans and clinical exams before discharge, and follow up at day 90 to assess recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
acetylsalicylic acid (aspirin) tablets
What this could lead to
If aspirin works, it could offer a simple, low-cost way to prevent strokes in people undergoing coiling for unruptured brain aneurysms.
What could go wrong
The trial is still testing this idea, and aspirin may not reduce stroke risk or could increase bleeding complications. Results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 440 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2020

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Unruptured intracranial aneurysm suitable for coiling-only (primary coiling or balloon-assisted) as a primary treatment. * Functionally independent at baseline (modified Rankin scale \<3). * Informed consent and availability of the subject for the entire study period. Exclusion Criteria: 1. Planned complex aneurysm treatment including use of any device that requires post-operative antiplatelet therapy (stent-assisted coiling or flow-diverter device), or endovascular vessel sacrifice. 2. Dissecting or mycotic brain aneurysm. 3. Any ongoing ischemic symptoms such as transient ischemic attacks, minor strokes, or stroke-in-evolution within 2 weeks before randomization. 4. Allergy or contraindication to ASA. 5. Unable to take study drug orally for any reason. 6. Subjects already taking single or dual antiplatelet, warfarin, or any of the non-Vitamin K antagonist oral anticoagulants. 7. Subjects unable to undergo MRI imaging for any reason (e.g., severe claustrophobia or presence of metals). 8. Any other medical condition that the site investigator deems would put the subject at excessive risk by participation in the study (e.g. active bleeding, symptomatic peptic ulcer disease, liver or kidney failure, thrombocytopenia or coagulopathy) or an expected life expectancy less than one year, or that would result in an inability to collect radiological outcomes and clinical outcomes at 90 days. 9. Pregnancy or breastfeeding. 10. Prior enrollment in EVOLVE trial for another aneurysm. 11. Participation in another clinical trial of an investigational drug, device or procedure if the subject received the trial drug, device or procedure in the preceding 30 days from the anticipated coiling date.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Unruptured cerebral aneurysm are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain aneurysm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Unruptured cerebral aneurysm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Régional Universitaire de Tours

    RECRUITING

    Tours, Centre-Val de Loire, France

  • Dalhousie University

    RECRUITING

    Halifax, Nova Scotia, Canada

  • Foothills Medical Center

    RECRUITING

    Calgary, Alberta, T2N 2T9, Canada

  • McGill University

    RECRUITING

    Montreal, Quebec, Canada

  • McMaster University

    RECRUITING

    Hamilton, Ontario, Canada

  • Toronto St Michael's Hospital

    RECRUITING

    Toronto, Ontario, Toronto, Canada

  • Toronto Western Hospital

    RECRUITING

    Toronto, Ontario, Canada

  • U of Alberta

    RECRUITING

    Edmonton, Alberta, Canada

  • University of Saskatchewan

    RECRUITING

    Saskatoon, Saskatchewan, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.